Topical Roflumilast Foam 0.3% (ZORYVE)

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a mission-driven, commercial-stage company focused on delivering meaningful innovation in medical dermatology through novel topical therapies. Its strategy centers on a proprietary dermatology platform that optimizes formulation science to target biologically validated pathways, primarily PDE4, enabling high-efficacy, low-systemic absorption treatments. The company has achieved significant commercial and regulatory milestones, including six FDA approvals for its lead asset, roflumilast, and is advancing a robust pipeline across multiple inflammatory skin conditions. Arcutis aims to simplify disease management and elevate the standard of care for millions of patients globally.

Therapeutic Areas

Other Seborrheic Dermatitis Drugs